Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
